Entheon Biomedical

Entheon Biomedical Now Trading on Frankfurt Exchange

ENBI Profile

Entheon Biomedical Corp. is a biotechnology research and development company. It engages in developing and commercializing a portfolio of Dimethyltryptamine based psychedelic therapeutic products for the purposes of treating addiction and substance use disorders. The company was founded on June 17, 2019 and is headquartered in Coquitlam, Canada.

Recent News

Entheon Biomedical to be Included in First North American Psychedelic ETF

Vancouver, British Columbia–(Newsfile Corp. – January 22, 2021) –  Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce its inclusion in the Horizon North American Psychedelic ETF, the first ever psychedelic ETF of its kind. […]

Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants

Vancouver, British Columbia–(Newsfile Corp. – December 9, 2020) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the “Agreement“) with Psygen Labs Inc. (“Psygen“). Under the terms of the Agreement, Psygen will supply […]

Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific

Vancouver, British Columbia–(Newsfile Corp. – December 4, 2020) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces a strategic investment in Wonder Scientific Inc. (“Wonder Scientific”). Wonder Scientific’s team of University Researchers and Product Development experts create custom, naturally derived, […]

Entheon Biomedical Corp. Commences Trading on the Canadian Securities Exchange

Vancouver, British Columbia–(Newsfile Corp. – November 12, 2020) – Entheon Biomedical Corp. (CSE: ENBI) (formerly, MPV Exploration Inc.) (“Entheon” or the “Company“) is pleased to announce that, further to its news release dated November 5, 2020, the Company has commenced trading on the Canadian Securities Exchange (“CSE“) under the symbol “ENBI”. Timothy Ko, CEO of […]